CORDIS - Forschungsergebnisse der EU
CORDIS

The critical shift to single-cell formats in functional analyses of living cells

Ziel

The incredible potential of cell and immune therapy (CIT) is limited by technical challenges related to the standard analysis of immune cells in bulk, which neglects their heterogeneity. Single-cell functional resolution is essential to understand the full potential of immune cells. Current single-cell technologies are limited, low-throughput, high-cost and lack robustness, prohibitive for their implementation in CIT R&D, manufacturing and patient stratification. Samplix is developing Xplore, an all-in-one multiparameter single-cell analyser and sorter for screening, selection and expansion of immune cells based on functionality and potency. Xplore is a cost-effective solution that delivers higher throughput and sensitivity than current solutions, being compatible with CIT research workflows. Unlocking the full potential of CIT supports the faster and efficient development of new personalized therapies to treat serious diseases such as cancer, autoimmune diseases, and viral infections.

Koordinator

SAMPLIX ApS
Netto-EU-Beitrag
€ 2 500 000,00
Adresse
BREGNERODVEJ 96
3460 Birkerod
Dänemark

Auf der Karte ansehen

KMU

Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen).

Ja
Region
Danmark Hovedstaden Nordsjælland
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Gesamtkosten
€ 4 926 042,50